(S1 (S (S (NP (NP (JJ Telomere/telomerase) (NN interplay)) (PP (IN in) (NP (ADJP (ADJP (JJ virus-driven)) (CC and) (ADJP (JJ virus-independent))) (NN lymphomagenesis)))) (: :) (NP (ADJP (ADJP (JJ pathogenic)) (CC and) (ADJP (JJ clinical))) (NNS implications))) (. .)))
(S1 (S (S (NP (NN Telomerase)) (VP (VBZ is) (NP (NP (DT a) (NN ribonucleoprotein) (NN complex)) (VP (ADVP (RB critically)) (VBN involved) (PP (IN in) (NP (ADJP (ADJP (VBG extending)) (CC and) (ADJP (VBG maintaining))) (NNS telomeres))))))) (. .)))
(S1 (S (S (PP (IN Unlike) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NP (JJ somatic) (NNS cells)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NN hTERT)) (CC and) (NP (NN telomerase) (NN activity))) (VP (VBP are) (ADVP (RB generally)) (ADJP (JJ silent))))))))) (, ,) (NP (JJ normal) (NNS lymphocytes)) (VP (VBP show) (NP (NP (JJ transient) (JJ physiological) (NN hTERT) (NN expression)) (CC and) (NP (NN telomerase) (NN activity))) (PP (VBG according) (PP (TO to) (NP (PRP$ their) (JJ differentiation/activation) (NN status)))))) (. .)))
(S1 (S (S (PP (IN During) (NP (NN lymphomagenesis))) (, ,) (NP (NP (NN induction)) (PP (IN of) (NP (NP (JJ persistent) (NN telomerase) (NN expression)) (CC and) (NP (NN activity))))) (VP (MD may) (VP (VB occur) (PP (IN before) (CC or) (PP (IN after) (NP (NN telomere) (NN shortening)))) (, ,) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (DT the) (JJ different) (NNS mechanisms)) (SBAR (WHPP (IN through) (WHNP (WDT which))) (S (NP (NN transforming) (NNS factors/agents)) (VP (MD may) (VP (VB activate) (NP (NN telomerase))))))))))))) (. .)))
(S1 (S (S (NP (JJ Available) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN timing)) (PP (IN of) (NP (NN telomerase) (NN activation)))) (VP (MD may) (VP (VB allow) (NP (DT the) (NN distinction)) (PP (IN of) (NP (CD two) (JJ different) (JJ lymphomagenetic) (NNS models))))))))) (: :) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (NP (DT an) (JJ early) (NN activation)) (PP (IN of) (NP (NP (NN telomerase)) (PP (IN via) (NP (NP (JJ exogenous) (NNS regulators)) (PP (IN of) (NP (NN hTERT))) (, ,) (PP (IN along) (IN with) (NP (NP (DT an) (VBN increased) (NN lymphocyte) (NN growth)) (CC and) (NP (NP (DT a) (JJ subsequent) (NN selection)) (PP (IN of) (NP (NP (NNS cells)) (PP (IN with) (NP (VBN increased) (VBG transforming) (NN potential))))))))))))) (VP (MD may) (VP (VB characterize) (NP (JJ several) (JJ virus-related) (JJ lymphoid) (NNS malignancies))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (DT a) (JJ progressive) (NN shortening)) (PP (IN of) (NP (NNS telomeres))) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (JJ genetic) (NN instability)) (SBAR (WHNP (WDT which)) (S (VP (VBZ favors) (NP (NP (DT a) (JJ subsequent) (NN activation)) (PP (IN of) (NP (NN telomerase)))) (PP (IN via) (NP (JJ endogenous) (NNS regulators)))))))))) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (JJS most) (JJ virus-unrelated) (JJ lymphoid) (NNS tumors)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS models)) (VP (MD may) (VP (VB have) (NP (ADJP (RB clinically) (JJ relevant)) (NNS implications)) (, ,) (PP (ADVP (RB particularly)) (IN for) (NP (NP (DT the) (NN tailoring)) (PP (IN of) (NP (NP (JJ therapeutic) (NNS strategies)) (VP (VBG targeting) (NP (NN telomerase)))))))))) (. .)))
